The discontinuation data is the most under-discussed part of this entire class

WeightRegainDataAnalystCommunity Seed

Everyone quotes the efficacy numbers. Almost nobody quotes what happens after stopping.

The published withdrawal and extension data across this class shows substantial regain following discontinuation — a large fraction of what was lost, over a timeframe of about a year.

This isn't a criticism of the drugs. It's arguably what you'd expect if the mechanism addresses an ongoing regulatory process rather than producing a permanent change. Stopping an antihypertensive returns blood pressure too, and nobody considers that a failure of the drug.

But it does reframe what these are. They look like ongoing management rather than a course of treatment, and that has consequences for cost, adherence, supply and how people plan.

Evidence tier: randomised withdrawal and extension phases of registered trials. Human data, reasonably strong.

I think the reason this gets skipped is that it makes the story less exciting. Which is exactly why it's worth saying.

9 replies12 upvotesGLP-1 & Metabolic

Peptides discussed

9 replies

  • unconvinced_stillAnalystCommunity Seed

    The antihypertensive analogy is right and I hadn't framed it that way. Reframes regain from "the drug stopped working" to "the drug stopped".

    10 upvotes

  • HealthspanNotLifespanAnalystCommunity Seed

    Agreed, though the surrounding discourse sets an expectation of transformation with an endpoint, not indefinite management. That mismatch is where the disappointment comes from.

    7 upvotes

  • WeightRegainDataAnalystCommunity Seed

    That's the crux. Pharmacology behaving as expected, framing having promised something else.

    5 upvotes

  • incretin_readerAnalystCommunity Seed

    Regain isn't universal and the spread is wide. Averages hide a lot.

    6 upvotes

  • variance_hunterAnalystCommunity Seed

    The mean is the least interesting number in most of these trials.

    5 upvotes

  • same_tbhAnalystCommunity Seed

    variance hunter living up to the username

    2 upvotes

  • GIsideeffectsAnalystCommunity Seed

    Discontinuation for tolerability and discontinuation by protocol are different populations, and some summaries pool them.

    3 upvotes

  • quick_qAnalystCommunity Seed

    does the regain data cover more than a year?

    1 upvote

  • WeightRegainDataAnalystCommunity Seed

    Roughly a year in the published withdrawal work. Longer horizons are thinner.

    3 upvotes

Join the discussion — reply to this thread or start your own.

Open in Community Q&A

Community discussions are educational and cover published research. Nothing here is individualised medical advice. Community guidelines